Objective To analyze the efficacy and safety of small molecule tyrosine kinase inhibitor (TKI) combined with monoclonal antibody of programmed death receptor-1 (PD-1) in the treatment of patients with advanced malignant tumors of digestive system.
Methods The efficacy and adverse reactions, tumor growth rate and correlation between adverse reactions and efficacy in the patients with advanced malignant tumors of digestive system by combined treatment of TKI and monoclonal antibody of PD-1 from March 2019 to February 2021 in the Internal Department of Oncology of the First Hospital of China Medical University were analyzed retrospectively.
Results Among the 30 included patients, 25 patients were available for efficiency evaluation. The objective response rate (ORR) and disease control rate (DCR) of cases with gastric and intestinal cancers were 0 and 58.33% respectively, the ORR and DCR of cases with liver cancer were 50.00% and 100.00% respectively, the ORR and DCR of cases with pancreatic cancer were 33.30% and 100.00% respectively, and the ORR and DCR of cases with esophageal cancer were 50.00% and 100.00% respectively. There were significant correlations between tumor growth rate, immune related adverse events and DCR (P < 0.05).
Conclusion TKI combined with monoclonal antibody of PD-1 shows a certain anti-tumor activity in the treatment of patients with advanced malignant tumors of digestive system, and the patients with liver cancer are prone to have more benefits from combined treatment. In the course of combined therapy, patients with slow tumor growth rate have better curative effect.
DownLoad: